Litigation
Adapt Pharma Operations Ltd. v. Teva Pharmaceuticals USA, Inc.
affirmed2020-2106
Auto-generating section 1 of 5: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Terminated
- 2022-02-10
Patents at issue (1)
Plaintiffs (1)
Defendants (1)
Summary
Federal Circuit appeal from the D.N.J. invalidity judgment. On February 10, 2022, the court affirmed, finding no error in the obviousness conclusion as to the asserted claims including U.S. 9,629,965 claims 21, 24, and 25; Newman, J., dissented.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
In the news
What the press has reported about this case, summarized with links to the source articles.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).